BCDA - biocardia.com Operating profit before deduction of amortization

BioCardia, Inc. (BCDA) is developing the innovative CardiAMP platform for myocardial regeneration via cell transplantation. The EBITDA_Co trend on GURU.Markets captures profit dynamics, where 0.00 indicates the current level. This is supported by alliances with cardiac centers to create drug delivery systems, providing access to a massive market for severe pathology therapies with high sales potential.

Real cash flow from core operations is critical for BioCardia, Inc. (BCDA), as the precision logistics of biotherapeutic systems require significant capital expenditures to maintain margins. Monitoring operating profit in cash terms allows for an assessment of actual solvency through the difference between operating income and expenses, where an upward trend confirms the issuer's financial stability and the absence of liquidity gap risks.